Defibrotide Sodium

CHEMBL3707226 Phase 4 Zugelassen Oligonucleotide

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A sodium salt form of defibrotide, a medication derived from DNA that protects the cells lining blood vessels. It is used to treat severe hepatic veno-occlusive disease, a life-threatening liver complication that can follow stem cell transplantation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A sodium salt form of defibrotide, a medication derived from DNA that protects the cells lining blood vessels. It is used to treat severe hepatic veno-occlusive disease, a life-threatening liver complication that can follow stem cell transplantation.

Yes, Defibrotide Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Oligonucleotide.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3707226. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Defibrotide Sodium auf PillFYI

Schnelldaten

Synonyme: 1

Externe Links

ChEMBL CHEMBL3707226

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.